| For Practicing Rheumatologists |
  See all
|
Article Summary
|
|
|
Balint, G.P., et al. - Overactivity of IL-6 plays a very important role in both the exsudative and proliferative phase of rheumatoid inflammation, joint destruction and osteoporosis. Blocking of IL-6 activity is a rational goal in the treatment of rheumatoid arthritis (RA). Tocilizumab (TCZ) is a humanized antibody against the soluble IL-6 receptor (sIL-6R) and membrane-bound IL-6 receptor (mIL-6R), blocking these receptor complexes and preventing IL-6 transmembrane signaling
|
 |
|
| Read a Different Specialty |
 |
|
|
|
|
| Profession Index |
|
|
|
|
|
|
|
